Exicure, Inc. (XCUR) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Exicure (XCUR) by buying shares or fractional shares at any major US broker, or as one small holding in a healthcare or biotech basket. Exicure is a clinical-stage biotechnology company that has reinvented itself: once focused on spherical nucleic acid therapies, it now centers on hematologic diseases after acquiring assets tied to GPC-100 (burixafor), a small-molecule CXCR4 antagonist aimed at mobilizing stem cells for transplant in multiple myeloma patients. The single biggest thing to understand is that this is a tiny, pre-revenue, high-risk biotech that has faced Nasdaq listing-compliance issues and needs additional capital, so the stock is highly speculative and its future depends on both clinical progress and raising money.
XCUR stock price
As of 2026-07-14, Exicure, Inc. (XCUR) last closed at $1.78, down 74.7% over the past year. Over the past 52 weeks it has traded between $1.65 and $8.86.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Exicure, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Exicure, Inc. (XCUR) do?
Exicure is a clinical-stage biotechnology company whose identity has shifted dramatically. It was originally known for spherical nucleic acid (SNA) technology, but after those programs wound down it acquired assets from GPCR Therapeutics in January 2025 and repositioned itself around hematologic diseases. Its lead candidate is GPC-100, also called burixafor, a highly selective small-molecule antagonist of CXCR4, a receptor that helps retain hematopoietic stem cells in the bone marrow. The idea is to mobilize those stem cells more effectively so they can be collected for autologous transplant, initially in patients with multiple myeloma, with potential extensions to acute myeloid leukemia and other transplant or cell-and-gene-therapy settings.
The investment picture in 2026 is a mix of clinical encouragement and financial fragility. Exicure completed enrollment in and reported positive topline Phase 2 data for burixafor in multiple myeloma stem-cell mobilization, presented findings at the 2025 ASH annual meeting, and saw a related publication in a hematology journal in early 2026. At the same time, it received a Nasdaq notice in mid-2026 for failing to meet the minimum stockholders' equity requirement, giving it a window to submit a compliance plan, and its disclosures emphasize the need for additional capital to continue operations. As a pre-revenue company with no approved product, Exicure trades on clinical milestones, strategic decisions, and its ability to fund itself, not on sales, which makes it a highly speculative name.
What's driving Exicure, Inc. (XCUR)?
1. GPC-100 (burixafor) clinical progress
The core of the thesis is burixafor, a CXCR4 antagonist designed to mobilize hematopoietic stem cells faster for autologous transplant. Exicure has reported positive topline Phase 2 results in multiple myeloma and presented data at a major hematology meeting. Advancing toward later-stage trials and, eventually, potential registration is what could give the company real value. But every step requires successful trials and substantial funding, and stem-cell mobilization is a competitive niche with established options.
2. Capital and going-concern risk
Exicure's own disclosures stress the need for additional capital to support operations and clinical development. For a micro-cap biotech with no product revenue, funding is existential: without new money the programs cannot advance and the company cannot continue as it is. Any capital raise is likely to dilute existing holders, and unfavorable terms are common for small, distressed issuers. This financial fragility is arguably the single biggest near-term factor for the stock.
3. Nasdaq listing compliance
In mid-2026 Exicure received a Nasdaq notice for not meeting the minimum stockholders' equity requirement under the exchange's listing rules, with a deadline to submit a compliance plan and a possible cure period. Failing to regain compliance could ultimately threaten its Nasdaq listing, which would hurt liquidity and access to capital. Resolving this, likely through raising equity, is a live overhang that investors have to weigh alongside the clinical story.
4. Pipeline breadth and strategic direction
Beyond multiple myeloma, GPC-100 is being considered in settings such as acute myeloid leukemia, sickle cell disease, and other autologous-transplant or cell-and-gene-therapy uses where better stem-cell mobilization could help. Broader applicability is option value if the drug works. Exicure has also undergone board changes tied to its acquired assets and continues a strategic review. Direction and leadership choices, on top of the science, will shape whether the reinvented company can create durable value.
What are the risks to Exicure, Inc. (XCUR)?
The dominant risk is that Exicure is a pre-revenue, micro-cap biotech that has repeatedly reinvented itself and now depends on a single lead program plus fresh capital to survive. Its own filings flag the need for additional funding and raise going-concern-style concerns, so dilution or distress financing is a real possibility. A Nasdaq notice for failing the minimum stockholders' equity rule creates a delisting overhang that could impair liquidity if not cured. Clinical risk is high: positive Phase 2 data do not guarantee later-stage success or approval, and stem-cell mobilization already has approved competitors. The stock is thinly traded and volatile, prone to sharp moves on single announcements. None of this is investment advice.
How is Exicure, Inc. (XCUR) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Exicure, Inc.'s investor relations page or your broker.
- Stage: Clinical-stage: no approved product and minimal or no product revenue
- Lead asset: GPC-100 (burixafor), a CXCR4 antagonist for stem-cell mobilization; positive Phase 2 topline data reported in multiple myeloma
- Financial condition: Discloses need for additional capital; operating losses expected; verify latest cash runway in filings
- Listing status: Received a Nasdaq minimum stockholders' equity deficiency notice in mid-2026 with a compliance window; confirm current status
- Profitability: Not profitable; expected to keep losing money while it funds development
- Valuation lens: Trades on clinical milestones and financing, not earnings; no meaningful P/E for a pre-revenue biotech
Figures are qualitative and tied to the asOf date. Exicure is a rapidly changing micro-cap whose cash position, share count, and listing status can shift quickly with each raise or filing, so verify live numbers, going-concern language, and Nasdaq compliance status in the latest SEC filings and press releases before acting. Traditional earnings multiples are not meaningful here; the value is a bet on clinical success and on the company staying funded and listed.
Who competes with Exicure, Inc. (XCUR)?
Stem-cell mobilization agents
GPC-100 targets the same CXCR4 pathway as established mobilization agents used with G-CSF in transplant, most notably plerixafor and its generics. These approved options set the standard of care and the bar burixafor must clear on speed, efficacy, and cost, so incumbency in this niche is a direct competitive challenge.
Hematology and multiple myeloma drug developers
The broader multiple myeloma and hematologic-disease field is served by large and mid-cap biopharma companies with far deeper resources. While most are not direct mobilization rivals, they compete for clinical-trial patients, physician attention, and investor capital within the same therapeutic area.
Other clinical-stage micro-cap biotechs
As a tiny, pre-revenue, event-driven name, Exicure competes with a crowded field of small clinical-stage biotechs for scarce risk capital and attention. Many trade on single trial readouts and financing news rather than fundamentals, and Exicure's shares behave like others in that high-risk, speculative cohort.
How to invest in Exicure, Inc. (XCUR)
There are three common ways to get XCUR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so XCUR sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where XCUR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Exicure, Inc. (XCUR)
Exicure is a micro-cap, clinical-stage biotech reborn around a stem-cell-mobilization drug, with positive Phase 2 data offset by a pressing need for capital and Nasdaq listing-compliance concerns. It suits only investors comfortable with binary, pre-revenue biotech and going-concern risk.
Build a basket around XCUR with Walnut
Use Exicure, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is XCUR a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. Exicure is a highly speculative micro-cap biotech: the bull case is positive Phase 2 data for its stem-cell-mobilization drug and a fresh strategic focus, while the bear case is a pressing need for capital, likely dilution, and a Nasdaq listing-compliance overhang. Only investors comfortable with binary, pre-revenue biotech and possible going-concern risk should consider it, and size any position accordingly.
What does Exicure do now?
+
Exicure is a clinical-stage biotech now focused on hematologic diseases. After winding down its earlier spherical nucleic acid programs, it acquired assets tied to GPC-100 (burixafor), a CXCR4 antagonist designed to mobilize stem cells for autologous transplant, initially in multiple myeloma. It has no approved product, so it earns little or no product revenue and funds itself through capital raises.
What is GPC-100 (burixafor)?
+
GPC-100, also called burixafor, is a selective small-molecule antagonist of CXCR4, a receptor that helps hold hematopoietic stem cells in the bone marrow. Blocking it can help release those cells into the bloodstream so they can be collected for transplant. Exicure has reported positive Phase 2 topline results using it, combined with other agents, for stem-cell mobilization in multiple myeloma patients.
Why did Exicure change its business focus?
+
Exicure's original spherical nucleic acid programs did not reach the market, and the company restructured. In January 2025 it acquired assets from GPCR Therapeutics, which brought in GPC-100 and shifted its focus to hematologic diseases and stem-cell mobilization. This kind of pivot is common among small biotechs that need a new lead program after earlier efforts stall.
What is the Nasdaq compliance issue about?
+
In mid-2026 Exicure received a notice from Nasdaq that it did not meet the minimum stockholders' equity requirement for continued listing. The company was given a window to submit a compliance plan and could receive additional time to regain compliance. If it cannot cure the deficiency, its Nasdaq listing could be at risk, which would hurt liquidity, so verify the current status in its latest filings.
Does Exicure have enough money to keep going?
+
Exicure's disclosures emphasize the need for additional capital to support operations and clinical development, which is a warning sign for any pre-revenue company. Without new financing it cannot advance its programs, and raising money is likely to dilute existing shareholders. Always check the most recent cash-runway and going-concern commentary in its filings before assuming the company is well funded.
Does XCUR pay a dividend?
+
No. Exicure is a loss-making, clinical-stage biotech that needs its cash for development and does not pay a dividend. Investors hold it for the possibility of clinical and strategic upside, not for income, and given its financial condition income should not be part of the thesis.
What are the main risks of investing in XCUR?
+
The biggest risks are financial: Exicure is pre-revenue, flags a need for more capital, and faces a Nasdaq stockholders' equity deficiency, so dilution or a listing loss are real possibilities. Clinical risk is also high, since positive Phase 2 data do not guarantee later success or approval and it competes with approved mobilization agents. As a thinly traded micro-cap, the stock can move sharply on single announcements.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Exicure, Inc.'s investor relations page or your broker before making investment decisions.